IP Library Patent Application 16765601
Patent Application
App. No. 16/765,601

ASYMMETRIC PCR METHODS, PRIMERS AND KITS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/765,601
Abstract

The disclosure provides an asymmetric PCR amplification method for preparation of single-stranded product and primers and kits useful therefor.

Claims (47)

1 . A method for production of single stranded DNA amplicons via an asymmetric polymerase chain reaction (PCR), comprising the steps of:

(a) subjecting an initial mixture to a first phase of thermal cycling under amplifying PCR conditions, said initial mixture comprising:

(i) a nucleic acid sample;

(ii) an Asymmetric Primer Pair,

(iii) a thermostable DNA polymerase, and

(iv) PCR Reagents,

wherein the first phase of thermal cycling comprises cycling through at least three temperatures, said three temperatures comprising:

(1) a first temperature above the T m of the target nucleic acid for denaturation,

(2) a second temperature below the T m of the Unextended Primer for primer annealing, and

(3) a third temperature suitable for extension by the thermostable DNA polymerase,

thereby producing an intermediate mixture, said intermediate mixture comprising DNA amplicons extended from both the Unextended Primer and the Extended Primer if the target nucleic acid is present in the sample;

(b) subjecting the intermediate mixture to a second phase of thermal cycling, said second phase of thermal cycling comprising cycling through:

(1) a fourth temperature above the T m of the double stranded DNA amplicons for denaturation,

(2) a fifth temperature that is

(i) below the T m of the Extended Primer,

(ii) above the T m of the Unextended Primer and

(iii) suitable for extension by the thermostable DNA polymerase, thereby producing a final mixture, said final mixture comprising single stranded DNA amplicons if the target nucleic acid is present in the sample.

2 . The method of claim 1 , wherein step (a) is preceded by an initial denaturation period, optionally wherein initial denaturation is carried out at the first temperature.

3 . The method of claim 1 , wherein step (b) is followed by an additional extension period, optionally wherein the additional extension is carried out at the fifth temperature.

4 . The method of claim 1 , wherein the first and fourth temperatures are the same and/or the third and fifth temperatures are the same.

5 . The method of claim 1 , wherein the “B” region of the Extended Primer is the complement of an inverted repeat of at least a portion of the “A” region or is the complement of a direct repeat of at least a portion of the “A” region.

6 . The method of claim 1 , wherein the Unextended Primer does not have a 5′ tail extension or has a 5′ tail extension of 3 nucleotides or less.

7 . The method of claim 1 , wherein the Extended Primer comprises a “C” region, optionally wherein the “C” region, alone or in combination with the flanking “A” and/or “B” region nucleotides, forms a recognition site for a restriction endonuclease.

8 . The method of claim 1 , wherein the T m of the Extended Primer is greater than the T m of the Unextended Primer by at least 8° C.

9 . The method of claim 1 , wherein the T m of the “A” region of the Extended Primer and the T m of the Unextended Primer vary by no more than 3° C.

10 . The method of claim 1 , wherein

(a) the first temperature is 95° C.;

(b) the second temperature is 58° C.;

(c) the third temperature is 72° C.;

(d) the fourth temperature is 95° C.;

(e) the fifth temperature is 72° C.; or

(f) any combination of (a)-(e).

11 . The method of claim 1 , wherein the DNA amplicons extended from both the Unextended Primer and the Extended Primer in the intermediate mixture are hybridized to one another to form double stranded DNA amplicons.

12 . The method of claim 1 , wherein the nucleic acid sample is a test nucleic acid sample.

13 . The method of claim 1 , wherein the nucleic acid sample is a control nucleic acid sample.

14 . The method of claim 1 , which is a multiplex PCR reaction.

15 . The method of claim 1 , wherein the PCR is performed in the absence of a Generic Primer.

16 . The method of claim 1 , wherein the first phase results in exponential amplification of both strands of the target nucleic acid and/or the second phase results in linear amplification of a single strand of the target nucleic acid.

17 . The method of claim 1 , wherein the Asymmetric Primer Pair comprises sequences complementary to bacterial sequences or fungal DNA sequences.

18 . The method of claim 1 , wherein the sample is a biological sample, optionally wherein the biological sample is:

(a) blood or a sample processed, extracted or fractionated therefrom;

(b) peritoneal dialysis fluid or a sample processed, extracted or fractionated therefrom;

(c) is urine or a sample processed, extracted or fractionated therefrom;

(d) sputum or a sample processed, extracted or fractionated therefrom; or

(e) a wound swab or a sample processed, extracted or fractionated therefrom.

19 . The method of claim 1 , wherein the sample is an environmental sample.

20 . The method of claim 1 , which further comprises detecting the single stranded PCR amplicon.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2024
From: IP SUCCESSOR FUND 21 L.P.
To: SAFEGUARD BIOSYSTEMS HOLDINGS LIMITED
Reel/Frame 069084/0644 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2024
From: MLC50 LP INC.
To: SAFEGUARD BIOSYSTEMS HOLDINGS LIMITED
Reel/Frame 069084/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2024
From: SAFEGUARD BIOSYSTEMS HOLDING LIMITED
To: SAFEGUARD DX LIMITED
Reel/Frame 069088/0245 →
SECURITY INTEREST Recorded Aug 16, 2024
From: SAFEGUARD BIOSYSTEMS HOLDINGS LIMITED
To: MLC50 LP INC.
Reel/Frame 068317/0453 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SAFEGUARD BIOSYSTEMS HOLDINGS LIMITED
To: IP SUCCESSOR FUND 21 L.P.
Reel/Frame 055411/0940 →